Bioinformatics and Computational Biology Core

项目概要 阿尔茨海默氏病 (AD) 影响着全球约 4000 万人，是最常见的疾病形式 痴呆症主要见于老年人。 AD 是一种具有高度异质性的疾病，具有主要症状 包括多年来记忆和认知领域的逐渐恶化，最终导致死亡 诊断后约 3-9 年。在过去的几十年里，许多假设被提出作为潜在的 AD 的机制涉及多种生物过程，如蛋白质发病机制、线粒体 异常、病毒感染和其他神经胶质细胞介导的免疫反应。然而，该病的病因 其作用机制尚不明确，目前AD尚无根治性治疗方法。过去期间 多年来，AD 研究界做出了多项努力来确定潜在的药物靶点。 其中，AMP ADis 负责根据以下证据生成候选药物靶点： 多项研究。这些项目积累了大量数据，需要更深入的分析 结合广泛的下游药物开发技术来完善候选目标清单，并且 确定潜在的新靶点以及可能的药物。 ADDD项目旨在建立整个工作流程 并雄心勃勃地发现治疗 AD 的新药。作为我们 ADDD 项目整体努力的一部分， 生物信息学和计算生物学核心（BCB 核心）将在该团队中发挥关键作用。 BCB 核心将扮演三个主要角色。首先，BCB Core将引领基础设施的发展 管理、处理、分析、可视化和共享来自该项目以及公共的大型 AD 数据集 来源。其次，BCB核心将开发和建立先进、新颖的数据集成方法 预测和优先考虑可药物靶点以及潜在的 AD 候选药物的再利用。最后但是 最重要的是，BCB Core将为整个项目提供生物信息学数据处理和分析支持 通过密切合作和协调，覆盖 AD 药物靶点识别和测试的生命周期 与 ADDD 中心的其他核心。

Project Summary Alzheimer’s disease (AD) affects about 40 million people worldwide today, and is the most common form of dementia found predominantly in elderly people. AD is a highly heterogeneous disease with major symptoms including progressive memory and cognitive domain deterioration over years, which eventually leads to death about 3-9 years after diagnosis. During the past few decades, many hypotheses have been proposed as potential mechanisms for AD, which involve multiple biological processes such as proteopathogenesis, mitochondrial abnormality, viral infection, and other glia cell-mediated immunological response. However, the disease etiology and mechanism still remain unclear, and currently, there is still no curative treatment for AD. During the past years, multiple endeavors have been taken by the AD research community to identify potential drug targets. Among them, AMP ADis leading the charge of generating drug target candidates based on evidences from multiple studies. With the large amount of data accumulated from these projects, it calls for deeper analysis coupled with extensive downstream drug development technologies to refine the target candidate lists and also identify potential new targets as well as possible drugs. The ADDD project aims to establish the entire workflow for this process and ambitiously discover new drugs for AD. As part of the overall effort of the our ADDD project, the Bioinformatics and Computational Biology Core (BCB Core) will play a critical role in this team. The BCB Core will play three major roles. First, the BCB Core will lead the development of the infrastructure enabling curation, processing, analysis, visualization, and sharing of large AD datasets from this project as well as public sources. Secondly, the BCB Core will develop and establish advanced and novel data integration methods for predicting and prioritizing druggable targets as well as potential repurposing drug candidates for AD. Last but not the least, the BCB Core will provide bioinformatics data processing and analysis support for the entire project covering the lifecycle of the AD drug target identification and testing by closely collaborating and coordinating with other cores for the ADDD center.